Der Ophthalmologe

, Volume 115, Issue 4, pp 293–301 | Cite as

Stellungnahme des BVA, der DOG und der RG zur Therapie chorioidaler Neovaskularisationen bei anderen Erkrankungen als der neovaskulären altersabhängigen Makuladegeneration

Stand Oktober 2017
  • Berufsverband der Augenärzte Deutschlands e. V. (BVA)
  • Deutsche Ophthalmologische Gesellschaft (DOG)
  • Retinologische Gesellschaft e. V. (RG)
Leitlinien, Stellungnahmen und Empfehlungen
  • 68 Downloads

Statement from the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration

October 2017

Notes

Redaktionskomitee

Dr. Martin Gliem, Universitäts-Augenklink Bonn (federführend) Prof. Dr. Bernd Bertram, Augenarztpraxis Aachen Prof. Dr. Norbert Bornfeld, Universitäts-Augenklinik Essen Prof. Dr. Frank G. Holz, Universitäts-Augenklink Bonn Prof. Dr. Mathias Maier, Universitäts-Augenklinik TU München Prof. Dr. Daniel Pauleikhoff, Augenabt. am St.-Franziskus Hospital Münster

Einhaltung ethischer Richtlinien

Interessenkonflikt

Siehe Tab. 1 im Anhang.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY (2012) Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 31:495–525CrossRefPubMedGoogle Scholar
  2. 2.
    Williams KM, Verhoeven VJ, Cumberland P et al (2015) Prevalence of refractive error in Europe: the European Eye Epidemiology (E(3)) Consortium. Eur J Epidemiol 30:305–315CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mirshahi A, Ponto KA, Laubert-Reh D et al (2016) Myopia and cognitive performance: results from the Gutenberg Health Study. Invest Ophthalmol Vis Sci 57:5230–5236CrossRefPubMedGoogle Scholar
  4. 4.
    Wolfram C, Hohn R, Kottler U et al (2014) Prevalence of refractive errors in the European adult population: the Gutenberg Health Study (GHS). Br J Ophthalmol 98:857–861CrossRefPubMedGoogle Scholar
  5. 5.
    Xu L, Li J, Cui T et al (2005) Refractive error in urban and rural adult Chinese in Beijing. Ophthalmology 112:1676–1683CrossRefPubMedGoogle Scholar
  6. 6.
    Liu HH, Xu L, Wang YX, Wang S, You QS, Jonas JB (2010) Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing Eye Study. Ophthalmology 117:1763–1768CrossRefPubMedGoogle Scholar
  7. 7.
    Miller DG, Singerman LJ (2001) Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 12:222–224CrossRefPubMedGoogle Scholar
  8. 8.
    Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P (2013) Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina 33:1300–1314CrossRefPubMedGoogle Scholar
  9. 9.
    Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P (2013) An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet 4:14CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gliem M, Muller PL, Birtel J, Hendig D, Holz FG, Charbel Issa P (2016) Frequency, phenotypic characteristics and progression of atrophy associated with a diseased Bruch’s membrane in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci 57:3323–3330CrossRefPubMedGoogle Scholar
  11. 11.
    Finger RP, Fenwick E, Marella M et al (2011) The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum. Health Qual Life Outcomes 9:113CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Daruich A, Matet A, Dirani A et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118CrossRefPubMedGoogle Scholar
  13. 13.
    Mrejen S, Spaide RF (2013) Optical coherence tomography: imaging of the choroid and beyond. Surv Ophthalmol 58:387–429CrossRefPubMedGoogle Scholar
  14. 14.
    Spaide RF, Campeas L, Haas A et al (1996) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103:2070–2079 (discussion 2079–80)CrossRefPubMedGoogle Scholar
  15. 15.
    Bouzas EA, Karadimas P, Pournaras CJ (2002) Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 47:431–448CrossRefPubMedGoogle Scholar
  16. 16.
    Bousquet E, Beydoun T, Rothschild PR et al (2015) Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina 35:2505–2515CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yannuzzi LA (2010) Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 149:361–363CrossRefPubMedGoogle Scholar
  18. 18.
    Peiretti E, Ferrara DC, Caminiti G, Mura M, Hughes J (2015) Choroidal neovascularization in caucasian patients with longstanding central serous chorioretinopathy. Retina 35:1360–1367CrossRefPubMedGoogle Scholar
  19. 19.
    Mansour AM, Arevalo JF, Ziemssen F et al (2009) Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 148(e2):310–316CrossRefPubMedGoogle Scholar
  20. 20.
    Perentes Y, Van Tran T, Sickenberg M, Herbort CP (2005) Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm 13:219–224CrossRefPubMedGoogle Scholar
  21. 21.
    Kleiner RC, Ratner CM, Enger C, Fine SL (1988) Subfoveal neovascularization in the ocular histoplasmosis syndrome. A natural history study. Retina 8:225–229CrossRefPubMedGoogle Scholar
  22. 22.
    Brown J Jr., Folk JC, Reddy CV, Kimura AE (1996) Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 103:1100–1105CrossRefPubMedGoogle Scholar
  23. 23.
    Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A (2007) Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology 114:606–614CrossRefPubMedGoogle Scholar
  24. 24.
    Wood CM, Richardson J (1990) Chorioretinal neovascular membranes complicating contusional eye injuries with indirect choroidal ruptures. Br J Ophthalmol 74:93–96CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chen CJ, Urban LL, Nelson NC, Fratkin JD (1998) Surgical removal of subfoveal iatrogenic choroidal neovascular membranes. Ophthalmology 105:1606–1611CrossRefPubMedGoogle Scholar
  26. 26.
    Chan WM, Li KK, Liu DT, Lai TY, Chong KK, Lam DS (2003) Photodynamic therapy with verteporfin in laser-induced choroidal neovascularization. Am J Ophthalmol 136:565–567CrossRefPubMedGoogle Scholar
  27. 27.
    Marano F, Deutman AF, Leys A, Aandekerk AL (2000) Hereditary retinal dystrophies and choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 238:760–764CrossRefPubMedGoogle Scholar
  28. 28.
    Sodi A, Murro V, Caporossi O et al (2015) Long-term results of photodynamic therapy for choroidal neovascularization in pediatric patients with best vitelliform macular dystrophy. Ophthalmic Genet 36:168–174CrossRefPubMedGoogle Scholar
  29. 29.
    Parodi MB, Iacono P, Cascavilla M, Zucchiatti I, Kontadakis DS, Bandello F (2010) Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Invest Ophthalmol Vis Sci 51:4358–4361CrossRefPubMedGoogle Scholar
  30. 30.
    Andrade RE, Farah ME, Costa RA (2003) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease. Am J Ophthalmol 136:1179–1181CrossRefPubMedGoogle Scholar
  31. 31.
    Gliem M, Muller PL, Mangold E et al (2015) Sorsby fundus dystrophy: novel mutations, novel phenotypic characteristics, and treatment outcomes. Invest Ophthalmol Vis Sci 56:2664–2676CrossRefPubMedGoogle Scholar
  32. 32.
    Ho AC, Yannuzzi LA, Pisicano K, DeRosa J (1995) The natural history of idiopathic subfoveal choroidal neovascularization. Ophthalmology 102:782–789CrossRefPubMedGoogle Scholar
  33. 33.
    Papastefanou VP, Pefkianaki M, Al Harby L et al (2016) Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma. Eye (Lond) 30:843–849CrossRefGoogle Scholar
  34. 34.
    Wolf S, Balciuniene VJ, Laganovska G et al (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121:682–692.e2CrossRefPubMedGoogle Scholar
  35. 35.
    Ikuno Y, Ohno-Matsui K, Wong TY et al (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR Study. Ophthalmology 122:1220–1227CrossRefPubMedGoogle Scholar
  36. 36.
    Lai TYY, Staurenghi G, Lanzetta P et al (2017) Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina  https://doi.org/10.1097/IAE.0000000000001744 Google Scholar
  37. 37.
    Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R (2013) Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4‑year outcome. Br J Ophthalmol 97:1447–1450CrossRefPubMedGoogle Scholar
  38. 38.
    Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F (2010) Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 128:437–442CrossRefPubMedGoogle Scholar
  39. 39.
    Zhu Y, Zhang T, Xu G, Peng L (2016) Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD011160.pub2 PubMedCentralGoogle Scholar
  40. 40.
    Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143:977–983CrossRefPubMedGoogle Scholar
  41. 41.
    Chhablani J, Kozak I, Pichi F et al (2015) Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina 35:2489–2497CrossRefPubMedGoogle Scholar
  42. 42.
    Kang HM, Koh HJ (2013) Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization. Am J Ophthalmol 155:713–9–719.e1Google Scholar
  43. 43.
    Vaz-Pereira S, Collaco L, De Salvo G, van Zeller P (2015) Intravitreal aflibercept for choroidal neovascularisation in angioid streaks. Eye (Lond) 29:1236–1238CrossRefGoogle Scholar
  44. 44.
    Hernandez-Martinez P, Dolz-Marco R, Alonso-Plasencia M, Abreu-Gonzalez R (2014) Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy. Graefes Arch Clin Exp Ophthalmol 252:1337–1339CrossRefPubMedGoogle Scholar
  45. 45.
    Toussaint BW, Kitchens JW, Marcus DM et al (2017) Intravitreal aflibercept injection for choroidal neovascularization due to presumed ocular histoplasmosis syndrome :the HANDLE study. Retina  https://doi.org/10.1097/IAE.0000000000001590 Google Scholar
  46. 46.
    Blinder KJ, Blumenkranz MS, Bressler NM et al (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2‑year results of a randomized clinical trial – VIP report no. 3. Ophthalmology 110:667–673CrossRefPubMedGoogle Scholar
  47. 47.
    Rogers AH, Duker JS, Nichols N, Baker BJ (2003) Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 110:1315–1320CrossRefPubMedGoogle Scholar
  48. 48.
    Wachtlin J, Heimann H, Behme T, Foerster MH (2003) Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol 241:899–906CrossRefPubMedGoogle Scholar
  49. 49.
    Harissi-Dagher M, Sebag M, Gauthier D, Marcil G, Labelle P, Arbour JD (2005) Photodynamic therapy in young patients with choroidal neovascularization following traumatic choroidal rupture. Am J Ophthalmol 139:726–728CrossRefPubMedGoogle Scholar
  50. 50.
    Chan WM, Lam DS, Wong TH et al (2003) Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology 110:2395–2402CrossRefPubMedGoogle Scholar
  51. 51.
    Lipski A, Bornfeld N, Jurklies B (2008) Photodynamic therapy with verteporfin in paediatric and young adult patients: long-term treatment results of choroidal neovascularisations. Br J Ophthalmol 92:655–660CrossRefPubMedGoogle Scholar
  52. 52.
    Peiretti E, Caminiti G, Serra R, Querques L, Pertile R, Querques G (2017) Anti-vegf therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous chorioretinopathy. Retina  https://doi.org/10.1097/IAE.0000000000001750 Google Scholar
  53. 53.
    Chan WM, Lam DS, Lai TY et al (2003) Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am J Ophthalmol 136:836–845CrossRefPubMedGoogle Scholar
  54. 54.
    Smretschnig E, Hagen S, Glittenberg C et al (2016) Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye (Lond) 30:805–811CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Berufsverband der Augenärzte Deutschlands e. V. (BVA)
    • 1
  • Deutsche Ophthalmologische Gesellschaft (DOG)
    • 2
  • Retinologische Gesellschaft e. V. (RG)
    • 3
  1. 1.Berufsverband der Augenärzte Deutschlands e. V.DüsseldorfDeutschland
  2. 2.Deutsche Ophthalmologische GesellschaftMünchenDeutschland
  3. 3.Retinologische Gesellschaft e. V.FreiburgDeutschland

Personalised recommendations